Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Early Utilization Patterns and Adverse Outcomes of Anti-Complement Therapy in Geographic Atrophy in the Clinical Setting.

Created on 17 Nov 2026

Authors

Jay Maturi, Joseph Tran, Josee Winsor, Nick Boucher, Adrienne W Scott

Published in

Ophthalmology. Retina. Nov 16, 2026. Epub Nov 16, 2026.

Abstract

To characterize early utilization patterns, development of neovascular AMD, and adverse events associated with pegcetacoplan and avacincaptad pegol for geographic atrophy in the clinical practice setting.
Retrospective, multi-center cohort study SUBJECTS: 20,316 eyes from 14,655 patients receiving baseline pegcetacoplan or avacincaptad pegol between August 2023 and July 2025 in the Vestrum Health Retina Database, observed through July 31, 2026.
Electronic health record data were analyzed to assess injection patterns, visual acuity (VA) over time, and safety. Multivariable logistic regression models identified factors associated with new-onset neovascular AMD.
Injection frequency, rate of new-onset neovascular AMD, incidence of endophthalmitis and intraocular inflammation (IOI), frequency of a 3-month gap in care, and rates of ≥30-letter-loss.
Among pegcetacoplan-only eyes, only 58.0% received a second injection within 60 days, and 54.9% received three injections within 120 days. Among avacincaptad pegol-only eyes, 18.6% received a 2nd injection within 35 days and 13.8% received a third injection within 70 days. 21.3% of eyes experienced a 90-day gap between retina appointments within the first 12 months. Of 10,744 eyes without baseline neovascular AMD, 705 (6.6%) developed new-onset neovascular AMD within 12 months of baseline anti-complement injection, after a mean of 3.57 injections. Compared to pegcetacoplan monotherapy, avacincaptad pegol monotherapy was associated with significantly lower rates of new-onset neovascular AMD (OR: 0.83, 95% CI: 0.70 - 0.99) within 12 months of baseline injection, while age ≥90 was associated with higher rates of new-onset neovascular AMD (OR: 1.28, 95% CI: 1.02-1.59) relative to patients <80. Among 10,419 eyes receiving ≥6 injections with available VA data at 12 months, mean VA change was -3.7 letters. Endophthalmitis rates within 30 days after injection were 0.16% and 0.05% for pegcetacoplan and 0.10% and 0.05% for avacincaptad pegol during baseline and subsequent injections, respectively. IOI occurred within 30 days after 0.23% of pegcetacoplan and 0.15% of avacincaptad pegol baseline injections, with ≥30-letter-loss in over half of cases.
Anti-complement use in clinical practice is characterized by frequent delays in early retreatment with notable conversion to neovascular AMD. Clinically significant adverse events warrant focused patient education and close monitoring with detailed return precautions.

PMID:
43039191
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement